Supplementary
: Change in body weight of mice during EGFR-TKI treatment in the LMC model with PC-9/ ffluc cells. LMC mice with PC9/ffluc were administered erlotinib (25 mg/kg), afatinib (5 mg/kg), or AZD9291 (6 mg/kg) once daily for 44 days as in Figure 3B and Figure 5B , and their body weights were measured every 5 days. Supplementary Figure S5 : Invalidity of pulsate high dose gefitinib therapies in LMC model with pC-9/ffluc cells. LMC mice with PC9/ffluc cells were administered gefitinib (12.5 mg/kg daily, 25 mg/kg every 2 days or 87.5 mg/kg once a week) for 6 weeks. Luminescence was evaluated as total flux (p/s: photons/second) and body weights were measured for groups of 4 mice every 5 days.

